UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors

Molecular cancer therapeutics, 2014-05, Vol.13 (5), p.1021-1031

2014

Volltextzugriff (PDF)

Development of PI3K inhibitors: lessons learned from early clinical trials

Nature reviews. Clinical oncology, 2013-03, Vol.10 (3), p.143-153

2013

Volltextzugriff (PDF)

Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy

Journal of clinical oncology, 2019-09, Vol.37 (25), p.2257-2269

2019

Volltextzugriff (PDF)

SLFN11 informs on standard of care and novel treatments in a wide range of cancer models

British journal of cancer, 2021-03, Vol.124 (5), p.951-962

2021

Volltextzugriff (PDF)

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer

Cancer research (Chicago, Ill.), 2016-04, Vol.76 (8), p.2301-2313

2016

Volltextzugriff (PDF)

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer

Science translational medicine, 2015-04, Vol.7 (283), p.283ra51

2015

Volltextzugriff (PDF)

INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors

Cancer discovery, 2022-02, Vol.12 (2), p.356-371

2022

Volltextzugriff (PDF)

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Nature communications, 2022-09, Vol.13 (1), p.5258-20, Article 5258

2022

Volltextzugriff (PDF)

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Breast cancer research : BCR, 2020-11, Vol.22 (1), p.120-120, Article 120

2020

Volltextzugriff (PDF)

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition

Cancer discovery, 2012-11, Vol.2 (11), p.1036-1047

2012

Volltextzugriff (PDF)

TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence

The Journal of clinical investigation, 2018-09, Vol.128 (9), p.3887-3905

2018

Volltextzugriff (PDF)

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2⁺ breast cancer patients

Proceedings of the National Academy of Sciences - PNAS, 2011-03, Vol.108 (9), p.3761-3766

2011

Volltextzugriff (PDF)

Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?

ESMO open, 2019, Vol.4 (2), p.e000480-e000480, Article e000480

2019

Volltextzugriff (PDF)

Modulation of telomere protection by the PI3K/AKT pathway

Nature communications, 2017-11, Vol.8 (1), p.1278-17, Article 1278

2017

Volltextzugriff (PDF)

BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance

Nature communications, 2019-12, Vol.10 (1), p.5661-12, Article 5661

2019

Volltextzugriff (PDF)

Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy

Clinical cancer research, 2012-05, Vol.18 (9), p.2603-2612

2012

Volltextzugriff (PDF)

MiR‐182‐3p targets TRF2 and impairs tumor growth of triple‐negative breast cancer

EMBO molecular medicine, 2023-01, Vol.15 (1), p.e16033-n/a

2023

Volltextzugriff (PDF)

Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs

Molecular cancer therapeutics, 2019-04, Vol.18 (4), p.771-779

2019

Volltextzugriff (PDF)

Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies

The Journal of experimental medicine, 2018-07, Vol.215 (7), p.1913-1928

2018

Volltextzugriff (PDF)

Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models

Scientific reports, 2023-02, Vol.13 (1), p.2710-2710, Article 2710

2023

Volltextzugriff (PDF)

Anti‐tumoural activity of the G‐quadruplex ligand pyridostatin against BRCA1/2‐deficient tumours

EMBO molecular medicine, 2022-03, Vol.14 (3), p.e14501-n/a

2022

Volltextzugriff (PDF)

Gain- and Loss-of-Function Mutations in the Breast Cancer Gene GATA3 Result in Differential Drug Sensitivity

PLoS genetics, 2016-09, Vol.12 (9), p.e1006279-e1006279

2016

Volltextzugriff (PDF)

1 – 25 von 220

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(209)
Mit Volltextzugriff
(184)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(121)
Life Sciences & Biomedicine
(108)
Humans
(100)
Female
(66)
Oncology
(56)
Animals
(48)
Breast Cancer
(44)
Mice
(43)
Tumors
(32)
Breast Neoplasms - Drug Therapy
(29)
Cell Line, Tumor
(29)
Breast Neoplasms - Genetics
(28)
Breast Neoplasms - Pathology
(28)
Xenograft Model Antitumor Assays
(27)
Mutation
(26)
Cancer
(23)
Cell Biology
(23)
Protein Kinase Inhibitors - Pharmacology
(22)
Antineoplastic Agents - Pharmacology
(21)
Adult
(18)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors

Development of PI3K inhibitors: lessons learned from early clinical trials

Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy

SLFN11 informs on standard of care and novel treatments in a wide range of cancer models

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer

Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer

INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition

TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2⁺ breast cancer patients

Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?

Modulation of telomere protection by the PI3K/AKT pathway

BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance

Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy

MiR‐182‐3p targets TRF2 and impairs tumor growth of triple‐negative breast cancer

Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs

Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies

Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models

Anti‐tumoural activity of the G‐quadruplex ligand pyridostatin against BRCA1/2‐deficient tumours

Gain- and Loss-of-Function Mutations in the Breast Cancer Gene GATA3 Result in Differential Drug Sensitivity

Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts

Suchergebnisse filtern